NO952912L - En ny osteoblastisk proliferativ faktor - Google Patents

En ny osteoblastisk proliferativ faktor

Info

Publication number
NO952912L
NO952912L NO952912A NO952912A NO952912L NO 952912 L NO952912 L NO 952912L NO 952912 A NO952912 A NO 952912A NO 952912 A NO952912 A NO 952912A NO 952912 L NO952912 L NO 952912L
Authority
NO
Norway
Prior art keywords
new
proliferative factor
osteoblastic
bone
diseaese
Prior art date
Application number
NO952912A
Other languages
English (en)
Norwegian (no)
Other versions
NO952912D0 (no
Inventor
Akira Kudo
Tohru Nakanishi
Masaharu Takigawa
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of NO952912D0 publication Critical patent/NO952912D0/no
Publication of NO952912L publication Critical patent/NO952912L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO952912A 1994-07-22 1995-07-21 En ny osteoblastisk proliferativ faktor NO952912L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (ja) 1994-07-22 1994-07-22 新規な骨芽細胞増殖因子

Publications (2)

Publication Number Publication Date
NO952912D0 NO952912D0 (no) 1995-07-21
NO952912L true NO952912L (no) 1996-01-23

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952912A NO952912L (no) 1994-07-22 1995-07-21 En ny osteoblastisk proliferativ faktor

Country Status (14)

Country Link
US (1) US6080720A (da)
EP (1) EP0704219B1 (da)
JP (1) JP3738281B2 (da)
KR (1) KR100361717B1 (da)
AT (1) ATE206930T1 (da)
AU (1) AU693567B2 (da)
CA (1) CA2154403A1 (da)
DE (1) DE69523250T2 (da)
DK (1) DK0704219T3 (da)
ES (1) ES2161809T3 (da)
FI (1) FI953514A (da)
HU (1) HU217082B (da)
NO (1) NO952912L (da)
PT (1) PT704219E (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8936804B2 (en) 2010-01-15 2015-01-20 Rutgers, The State University Of New Jersey Use of vanadium compounds to accelerate bone healing
EP2648718B1 (en) 2010-12-10 2019-05-08 Rutgers, the State University of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
US9931348B2 (en) 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
WO1995030434A1 (en) * 1994-05-06 1995-11-16 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
DE69523250T2 (de) 2002-07-04
US6080720A (en) 2000-06-27
NO952912D0 (no) 1995-07-21
ES2161809T3 (es) 2001-12-16
FI953514A0 (fi) 1995-07-20
KR960003741A (ko) 1996-02-23
JP3738281B2 (ja) 2006-01-25
HU217082B (hu) 1999-11-29
EP0704219B1 (en) 2001-10-17
DE69523250D1 (de) 2001-11-22
PT704219E (pt) 2002-03-28
DK0704219T3 (da) 2002-02-04
JPH0834744A (ja) 1996-02-06
AU693567B2 (en) 1998-07-02
FI953514A (fi) 1996-01-23
HU9502202D0 (en) 1995-09-28
HUT73185A (en) 1996-06-28
AU2710595A (en) 1996-02-01
EP0704219A3 (en) 1997-12-10
CA2154403A1 (en) 1996-01-23
ATE206930T1 (de) 2001-11-15
EP0704219A2 (en) 1996-04-03
KR100361717B1 (ko) 2003-07-07

Similar Documents

Publication Publication Date Title
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
HU9502193D0 (en) Combination treatment for inhibiting bone loss
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
BR9710250A (pt) Composto composição farmacêutica e processos para tratar uma infecção bacteriana em um paciente em necessidade de tal tratamento e para produzir um composto de bromotiacumicina
NO952912L (no) En ny osteoblastisk proliferativ faktor
EP0744176A3 (en) Methods for inhibiting bone loss
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
IT1276706B1 (it) Bicarbonati di derivati della 2,6-dimetilanilina, loro uso in terapia e composizioni farmaceutiche che li comprendono
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
AU639693B2 (en) Laser apparatus for treating bone and tooth tissue
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
NO974941L (no) Ny anvendelse av (S)-adenosyl-L-metionin(SAMe)
SG64899A1 (en) Method and composition for treatment of patients having decompsated liver disease
IT1262567B (it) Pirrolidin-2-oni,loro preparazione,composizioni farmaceutiche che li contengono e loro uso in terapia.
PL54844Y1 (en) Dental surgeon's syringe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application